|Systematic (IUPAC) name|
|Oral, intranasal, ophthalmic, intravenous, intramuscular|
|Bioavailability||38% through GI tract|
|Metabolism||Hepatic (monoamine oxidase)|
|Biological half-life||2.1–3.4 h|
|CAS Registry Number||
|ATC code||C01 R01, R01 (combinations), R01, S01, S01|
|Molecular mass||167.205 g/mol|
|(what is this?)|
Phenylephrine is a selective α1-adrenergic receptor agonist of the phenethylamine class used primarily as a decongestant, as an agent to dilate the pupil, and to increase blood pressure. Phenylephrine is marketed as an alternative for the decongestant pseudoephedrine, though clinical studies show Phenylephrine to be no more effective than placebo. Phenylephrine can also cause a decrease in heart rate through reflex bradycardia.
Phenylephrine is used as a decongestant sold as an oral medicine or as a nasal spray. It is a common ingredient in over-the-counter decongestants. Other decongestants include oxymetazoline (Brand name: Afrin) and Pseudoephedrine (Brand name: Sudafed)
Oral phenylephrine is extensively metabolized by monoamine oxidase, an enzyme that is present on the outside of cells, throughout the body. Compared to intravenous pseudoephedrine, phenylephrine has a reduced and variable bioavailability; only up to 38%. Phenylephrine is a sympathomimetic drug, which means that it mimics the actions of epinephrine (commonly known as adrenaline) or norepinephrine. Phenylephrine selectively binds to alpha receptors which cause blood vessels to constrict. Phenylephrine may cause side effects such as headache, reflex bradycardia, excitability, restlessness and cardiac arrhythmias. Phenylephrine is not suggested for use in patients with hypertension.
Phenylephrine is used as an alternative for pseudoephedrine in decongestant medicines due to pseudoephedrine's use in the illicit manufacture of methamphetamine. Its efficacy as an oral decongestant has been questioned, with multiple studies not being able to come to an agreement. Whereas pseudoephedrine causes both vasoconstriction and increase of mucociliary clearance through its nonspecific adrenergic activity, phenylephrine's selective α-adrenergic agonism causes vasoconstriction alone, creating a difference in their methods of action.
Hemorrhoids are caused by swollen veins in the rectal area. Phenylephrine can be used topically to prevent symptoms of hemorrhoids. Since phenylephrine is a vasoconstrictor, the blood vessels are narrowed, reducing the pain associated with hemorrhoids. Products for treatment may also include substances that will form a protective barrier over the inflamed area, resulting in less pain when feces is passed.
Phenylephrine is used as an eye drop to dilate the pupil to facilitate visualization of the retina. It is often used in combination with tropicamide as a synergist when tropicamide alone is not sufficient. Narrow-angle glaucoma is a contraindication to phenylephrine use. As a mydriatic, it is available in 2.5% and 10% minims. Phenylephrine eye drops are applied to the eye after a topical anestheic is applied.
Phenylephrine is commonly used as a vasopressor to increase the blood pressure in unstable patients with hypotension, especially resulting from septic shock. Such use is common in anesthesia or critical-care practices; it is especially useful in counteracting the hypotensive effect of epidural and subarachnoid anesthetics, as well as the vasodilating effect of bacterial toxins and the inflammatory response in sepsis and systemic inflammatory response syndrome. The elimination half life of phenylephrine is about 2.5 to 3.0 hours. The clinical effects of a single intravenous bolus dose of phenylephrine are short lived and needs to be repeated every 10–15 minutes. Commonly the drug is given as a carefully titrated intravenous infusion with a syringe pump or volumetric pump.
Because of its vasoconstrictive effect, phenylephrine can cause severe necrosis if it infiltrates the surrounding tissues. Because of this, it should be given through a central line if at all possible. Damage may be prevented or mitigated by infiltrating the tissue with the alpha blocker phentolamine by subcutaneous injection.
Phenylephrine is used by urologists to abort priapism. It is diluted significantly with normal saline and injected directly into the corpora cavernosa. The mechanism of action is to cause constriction of the blood vessels entering into the penis, thus causing decreased blood flow and relieving the priapism. An injection is given every 3–5 minutes. If priapism is not resolved in 1 hour, another form of therapy is considered.
The primary side effect of phenylephrine is hypertension. Patients with hypertension are typically advised to avoid products containing it. Prostatic hyperplasia can also be symptomatically worsened by use, and chronic use can lead to rebound hyperemia. Patients with a history of anxiety or panic disorders, or on anticonvulsant medication for epilepsy should not take this substance. The drug interaction might produce seizures. Some patients have been shown to have an upset stomach, severe abdominal cramping, and vomiting issues connected to taking this drug.
Phenylephrine is pregnancy category C. Due to the lack of studies done in animals and in humans, it is not known if there is harm to the fetus. Phenylephrine should only be given to pregnant women who have a clear need.
Because this medication is a sympathomimetic amine without beta-adrenergic activity, it does not increase contractility force and output of the cardiac muscle. It may increase blood pressure significantly to elicit a bradycardiac reflex through stimulation of vascular (likely carotid) baroreceptors (result: decrease heart rate).
A common side effect during IV administration is reflex bradycardia.
The increase in blood pressure effect of phenylephrine may be increased by drugs such as monoamine oxidase inhibitors, tricyclic antidepressants, and hydrocortisone. Patients taking these medications may need a lower dose of phenylephrine to achieve a similar increase in blood pressure.
Drugs that may decrease the effects of phenylephrine may include calcium channel blockers, ACE inhibitors and benzodiazepines. Patients taking these medications may need a higher dose of phenylephrine to achieve a comparable increase in blood pressure.
Substitute for pseudoephedrine
Pseudoephedrine and phenylephrine are both used as decongestants; and, until recently, pseudoephedrine was much more commonly available in the United States. This has changed because provisions of the Combat Methamphetamine Epidemic Act of 2005 placed restrictions on the sale of pseudoephedrine products to prevent the clandestine manufacture of methamphetamine. Since 2004, phenylephrine has been increasingly marketed as a substitute for pseudoephedrine; some manufacturers have changed the active ingredients of products to avoid the restrictions on sales. Phenylephrine has been off patent for some time, and many generic brands are available.
Questions about effectiveness
Pharmacists Leslie Hendeles and Randy Hatton of the University of Florida suggested in 2006 that oral phenylephrine is ineffective as a decongestant at the 10-mg dose used, arguing that the studies used for the regulatory approval of the drug in the United States in 1976 were inadequate to prove effectiveness at the 10-mg dose, and safety at higher doses.
A 2007 meta-analysis by Hatton et al concluded that the evidence for its effectiveness is insufficient, though another meta-analysis published shortly thereafter by researchers from GlaxoSmithKline found the standard 10-mg dose to be significantly more effective than a placebo, though as with other studies finding this, GSK has many products containing Phenylephrine which has caused some speculation to selective publishing or other controversial techniques. In a 2007 study by Wyeth Consumer Healthcare notes that 7 studies available in 1976 support the efficacy of phenylephrine at a 10 mg dosage.
Two studies published in 2009 examined the effects of phenylephrine on symptoms of allergic rhinitis by exposing sufferers to pollen in a controlled, indoor environment. Neither study was able to distinguish between the effects of phenylephrine or a placebo. Pseudoephedrine and loratadine-montelukast therapy were found to be significantly more effective than both phenylephrine and placebo.
- Horak, F.; Zieglmayer, P.; Zieglmayer, R.; Lemell, P.; Yao, R.; Staudinger, H.; Danzig, M. (11 November 2008). "A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber". Annals of Allergy, Asthma & Immunology (February 2009) 102 (2): 116–20. doi:10.1016/S1081-1206(10)60240-2. PMID 19230461.
- Day, J. H.; Briscoe, M. P.; Ratz, J. D.; Danzig, M.; Yao, R. (2009). "Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit". Annals of Allergy, Asthma & Immunology 102 (4): 328. doi:10.1016/S1081-1206(10)60339-0.
- "UCSF drug learning module: Phenylephrine". UCSF. UCSF. Retrieved 5 February 2015.
- "DrugBank: Phenylephrine (DB00388)". drugbank.ca. Retrieved 4 April 2015.
- Shih JC, Chen K; Chen (August 2004). "Regulation of MAO-A and MAO-B gene expression". Curr. Med. Chem. 11 (15): 1995–2005. doi:10.2174/0929867043364757. PMID 15279563.
- NZ Medicines and Medical Devices Safety Authority recommendation on phenylephrine (November 2004)
- "DailyMed - PHENYLEPHRINE HYDROCHLORIDE- phenylephrine hydrochloride injection". nih.gov. Retrieved 4 April 2015.
- "Neo-Synephrine Nasal Spray Drug Information, Professional". drugs.com. Retrieved 4 April 2015.
- "phenylephrine rectal". webmd.com. Retrieved 4 April 2015.
- Kanfer I, Dowse R, Vuma V (November 1993) “Pharmacokinetics of oral decongestants” Pharmacotherapy 13(6 pt 2) PMID 7507589
- Cooper, B. E. (2008). Review and Update on Inotropes and Vasopressors. AACN Advanced Critical Care, 19, 5–15.
- "DailyMed - PREPARATION H- cocoa butter and phenylephrine hydrochloride suppository". nih.gov. Retrieved 4 April 2015.
- "Priapism : American Urological Association". auanet.org. Retrieved 4 April 2015.
- Shen, Howard (2008). Illustrated Pharmacology Memory Cards: PharMnemonics. Minireview. p. 3. ISBN 1-59541-101-1.
- "Medscape: Medscape Access". medscape.com. Retrieved 4 April 2015.
- "Vazculep_FINAL_PI.pdf" (PDF). google.com. Retrieved 4 April 2015.
- Hilenmeyer, K. (30 January 2007). "All stuffed up". Southwest Florida Herald-Tribune.
- Heldeles, L. and Hatton, R. (2006). "Oral phenylephrine: An ineffective replacement for pseudoephedrine?". Journal of Allergy and Clinical Immunology 118 (1): 279–280. doi:10.1016/j.jaci.2006.03.002. PMID 16815167.
- Hatton, R.C. et al. (2007). "Efficacy and Safety of Oral Phenylephrine: A Systematic Review and Meta-Analysis" (abstract). Annals of Pharmacotherapy 41 (3): 381–390. doi:10.1345/aph.1H679. PMID 17264159. (published online Jan 2007)
- Kollar, C.; Schneider, H.; Waksman, J.; Krusinska, E. (2007). "Meta-analysis of the efficacy of a single dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold". Clinical Therapeutics 29 (6): 1057–1070. doi:10.1016/j.clinthera.2007.05.021. PMID 17692721.[unreliable medical source?]
- Desjardins, P.J. & Berlin, R.G. (2007). "Efficacy of phenylephrine". British Journal of Clinical Pharmacology 64 (4): 555–556. doi:10.1111/j.1365-2125.2007.02935.x.
- Drugs.com - Phenylephrine
- MedlinePlus: Phenylephrine
- U.S. National Library of Medicine: Drug Information Portal - Phenylephrine
- Neosynephrine Intravenous DIlution Guidelines: